

MELANOMA DISEASE SITE COMMITTEE

THE CHELSEA HOTEL, TORONTO, ON

ROOM: SCOTT

DATE: SUNDAY APRIL 29, 2018

TIME: 8:00 AM – 12:00 PM

CHAIR: DR. TERESA PETRELLA

SENIOR INVESTIGATOR : DR. JANET DANCEY

- | | | |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| 8:00 - 8:15 am | Welcome and Approval of 2017 Spring Meeting Minutes | T. Petrella |
| 8:15 - 8:40 am | Rapid Trial Updates (awaiting analysis or recently closed) | |
| | <ul style="list-style-type: none"> • MEC.3 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (ECOG) | T. Petrella |
| | <ul style="list-style-type: none"> • MEC.4 – Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma (Alliance) | M. Butler |
| | <ul style="list-style-type: none"> • MEC.5 – A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma (SWOG) | T. Petrella |
| | <ul style="list-style-type: none"> • IND225 – A Phase II Study of the Assessment of Response To Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker | T. Petrella |
| | <ul style="list-style-type: none"> • IND228 – A Phase II Study of Dervalumab and Tremelimumab in patients with advanced rare tumours | J. Dancey |
| 8:40 - 9:15 am | Trial Updates (ongoing / planned) | |
| | <ul style="list-style-type: none"> • IND224 – A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | T. Petrella |
| | <ul style="list-style-type: none"> • ME13 – A Randomized Phase III Study of Duration of Anti-PD1 Therapy in Metastatic Melanoma (STOP-GAP) | Tara Baetz/
Xinni Song |
| | <ul style="list-style-type: none"> • ME14 - Prophylactic mesalamine to reduce immune-related AEs with combination ipilimumab / nivolumab in metastatic melanoma | J. Walker |

9:15 – 9:45 am **Review of Melanoma Strategy / Priorities and Terms of Reference** J. Dancey

9:45 - 10:00 am **Break**

10:00 - 11:00 am **New Proposals / Updates**

- PILOT Update on the Melanoma Margins Trial (MelMarT):
A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma F. Wright
- The Terry Fox Research Institute Marathon of Hope Proposal Ian Watson
- EA6134: Dabrafenib and Trametinib followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab followed by Dabrafenib and Trametinib in treating patients with stage III-IV BRAFV600 Melanoma T. Petrella
- Neoadjuvant Trial Concept T. Petrella
- ALLIANCE meeting at ASCO M. Butler

11:00 - 12:00 pm Novartis Pipeline Bijoyesh Mookerjee
Senior Global Program Clinical Head

12:00 pm **Meeting Adjourned**

12:00 - 1:00 pm Executive Committee meeting to follow (closed)